How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?
Giuseppe Fallara(Istituti di Ricovero e Cura a Carattere Scientifico), Umberto Capitanio(Vita-Salute San Raffaele University), Federico Belladelli(IRCCS Ospedale San Raffaele), Alessandro Larcher(IRCCS Ospedale San Raffaele), Roberto Bertini, Alberto Martini(The University of Texas MD Anderson Cancer Center), Andrea Salonia(Vita-Salute San Raffaele University), Chiara Re(Vita-Salute San Raffaele University), Daniele Cignoli(Istituti di Ricovero e Cura a Carattere Scientifico), Daniele Raggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Montorsi(Vita-Salute San Raffaele University), Giacomo Musso(Istituti di Ricovero e Cura a Carattere Scientifico), Gianmarco Colandrea(Vita-Salute San Raffaele University), Giuseppe Rosiello(Vita-Salute San Raffaele University), Andrea Necchi(Vita-Salute San Raffaele University), Francesco Cei(Istituti di Ricovero e Cura a Carattere Scientifico), Laura Marandino, Alberto Briganti(Vita-Salute San Raffaele University), Giuseppe Basile(Vita-Salute San Raffaele University)
Cited by 8
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k